Solid Tumor, Adult Clinical Trial
Official title:
A Phase II Study to Evaluate the Efficacy and Safety of Cryoablation Combined With Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib for patients with previously treated solid tumors.
Recent studies have suggested that local destruction of tumor tissue by cryoablation induced activation and maturation of dendritic cells and tumor-specific T cells by cross-presentation of tumor antigens. While pd-1 blocking antibody interferes with PD-1 mediated T-cell regulatory signaling. And combination of pd-1 blocking antibody plus lenvatinib showed increased ORR in many types of human cancers. Therefore, the objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib in previously treated solid tumors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04551885 -
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05054348 -
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06088004 -
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
| Completed |
NCT04020185 -
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05071846 -
MVX-ONCO-2 in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05607199 -
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
|
Phase 1 | |
| Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
| Active, not recruiting |
NCT06026254 -
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
|
Phase 1 | |
| Recruiting |
NCT06144671 -
GT201 Injection For The Treatment Of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05276284 -
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04121442 -
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04221204 -
A Monotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03992326 -
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05435339 -
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
| Recruiting |
NCT06075849 -
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
|
Phase 1 | |
| Recruiting |
NCT04092673 -
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05586321 -
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
|
Phase 1 |